Controlled, cross-sectional MRI evaluation of joint status in severe haemophilia A patients treated with prophylaxis vs. on demand

Haemophilia

Volumn 21, Issue 2, 2015, Pages 171-179

  Oldenburg, J ^a,h   Zimmermann, R ^b,h   Katsarou, O ^c,h   Theodossiades, G ^d,h   Zanon, E ^e,h   Niemann, B ^a   Kellermann, E ^f   Lundin, B ^g   Franke, D ^h   Pollmann, H ^h   Mazzucconi, G ^h   Santagostino, E ^h   Tagliaferri, A ^h   Lopez, F ^h   Querol, F ^h   Berntorp, E ^h   Homstrom, M ^h   Chowdary, P ^h   Manco Johnson, M L ^h   Werk, M ^h   Walsch, R ^h   Schwartz, L ^h   more..

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Kurpfalz Hospital and Haemophilia Centre for Children and Adults   (Germany)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d HIPPOKRATION HOSPITAL   (Greece)

^e UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^f BAYER AG   (Germany)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h NONE   (United States)

Author keywords

Cross sectional study; Haemophilia; Joint status; Magnetic resonance imaging; On demand treatment; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8;

ADOLESCENT; ADULT; ANKLE; ARTICLE; BONE INJURY; CARTILAGE INJURY; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DETERIORATION; DISEASE SEVERITY; EVALUATION STUDY; GILBERT SCORE; HEMOPHILIA A; HUMAN; KNEE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; SCHOOL CHILD; SCORING SYSTEM; TREATMENT OUTCOME; YOUNG ADULT; CLINICAL TRIAL; COMPLICATION; CROSS-SECTIONAL STUDY; EUROPE; HEMARTHROSIS; MULTICENTER STUDY; PREMEDICATION; QUALITY OF LIFE;

ADOLESCENT; ADULT; CHILD; CROSS-SECTIONAL STUDIES; EUROPE; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PREMEDICATION; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84923106615     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12539     Document Type: Article

References (36)

1. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendation regarding the need for collaboration. Document #102. Available at: http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57%26contentid=307. Accessed January 14, 2014.
2. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
3. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
4. Liesner RJ, Khair K, Hann IM. The impact of prophylactic treatment on children with severe haemophilia. Br J Haematol 1996; 92: 973-8.
5. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J Intern Med 1997; 241: 395-400.
6. Brackmann HH, Eickhoff HJ, Oldenburg J, Hammerstein U. Long-term therapy and on-demand treatment of children and adolescents with severe haemophilia A: 12 years of experience. Haemostasis 1992; 22: 251-8.
7. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8: 83-9.
8. Berntorp E, Astermark J, Bjorkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9: 1-4.
9. Colvin BT, Astermark J, Fischer K et al. European principles of haemophilia care. Haemophilia 2008; 14: 361-74.
10. National Hemophilia Foundation. Medical and Scientific Advisory Council (MASAC) recommendations concerning prophylaxis (regular administration of clotting factor concentrate to prevent bleeding). Document #179. Available at: http://www.hemophilia.org/NHFWeb/Resource/StaticPages/menu0/menu5/menu57/masac179.pdf. Accessed January 14, 2014.
11. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
12. Ljung R. Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland. Haemophilia 1999; 5: 286-91.
13. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9.
14. Pergantou H, Platokouki H, Matsinos G et al. Assessment of the progression of haemophilic arthropathy in children. Haemophilia 2009; 16: 124-9.
15. Yu W, Lin Q, Guermazi A et al. Comparison of radiography, CT and MR imaging in detection of arthropathies in patients with haemophilia. Haemophilia 2009; 15: 1090-6.
16. Dobon M, Lucia JF, Aguilar C et al. Value of magnetic resonance imaging for the diagnosis and follow-up of haemophilic arthropathy. Haemophilia 2003; 9: 76-85.
17. Olivieri M, Kurnik K, Pfluger T, Bidlingmaier C. Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis. Haemophilia 2012; 18: 369-74.
18. Lundin B, Ljung R, Pettersson H. MRI scores of ankle joints in children with haemophilia-comparison with clinical data. Haemophilia 2005; 11: 116-22.
19. Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia 2004; 10: 383-9.
20. Feldman BM, Funk S, Lundin B et al. Musculoskeletal measurement tools from the International Prophylaxis Study Group (IPSG). Haemophilia 2008; 14(Suppl 3): 162-9.
21. Hassan TH, Badr MA, El-Gerby KM. Correlation between musculoskeletal function and radiological joint scores in haemophilia A adolescents. Haemophilia 2011; 17: 920-5.
22. Den Uijl IE, De Schepper AMA, Camerlinck M, Grobbee DE, Fischer K. Magnetic resonance imaging in teenagers and young adults with limited haemophilic arthropathy: baseline results from a prospective study. Haemophilia 2011; 17: 926-30.
23. Lundin B, Babyn P, Doria AS et al. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia 2005; 11: 109-15.
24. Lundin B, Manco-Johnson ML, Ignas DM et al. An MRI scale for assessment of haemophilic arthropathy from the International Prophylaxis Study Group. Haemophilia 2012; 18: 962-70.
25. Su Y, Wong WY, Lail A, Donfield SM, Konzal S, Gomperts E. Long-term major joint outcomes in young adults with haemophilia: interim data from the HGDS. Haemophilia 2007; 13: 387-90.
26. Royal S, Schramm W, Berntorp E et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
27. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART) [published correction appears in J Thromb Haemost. 2014;12: 119-122.]. J Thromb Haemost 2013; 11: 1119-27.
28. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
29. Manco-Johnson MJ, Nuss R, Geraghty S, Funk S, Kilcoyne R. Results of secondary prophylaxis in children with severe hemophilia. Am J Hematol 1994; 47: 113-7.
30. Cohen A, White E, Bernstein C et al. Effects of secondary prophylaxis in hemophilia children with frequent hemarthrosis. Transfusion (Paris) 1997; 37: 534-5.
31. Kraft J, Blanchette V, Babyn P et al. Magnetic resonance imaging and joint outcomes in boys with severe hemophilia a treated with tailored primary prophylaxis in Canada. J Thromb Haemost 2012; 10: 2494-502.
32. Groen W, van der Net J, Bos K et al. Joint health and functional ability in children with haemophilia who receive intensive replacement therapy. Haemophilia 2011; 17: 783-90.
33. Siegmund B, Richter H, Pollmann H. Need for prophylactic treatment in adult haemophilia A patients. Transfus Med Hemother 2009; 36: 283-8.
34. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia 2009; 15: 1014-21.
35. Miners AH, Sabin CA, Tolley KH, Lee CA. Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand's disease. J Intern Med 1998; 244: 515-22.
36. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.